Not all cancer patients need chemo — Ataraxis AI raised $20M to personalize treatment

Here’s a summary of the information from the text regarding Ataraxis AI:

Ataraxis AI Overview

• Sector: Artificial Intelligence in Cancer Care
• Focus: Predicting cancer presence and long-term outcomes to assess the need for aggressive treatments like chemotherapy.
• Co-Founders: Jan Witowski, Krzysztof Geras

Fundraising Details

• Recent Fundraise: $20.4 million Series A
• Date of Fundraise: Not explicitly stated, but recently (2024)
• Previous Fundraise: $4 million Seed Round (from stealth in the previous year)

Investors

• Lead Investor: AIX Ventures
• Participating Investors:
  • Thiel Bio
  • Founders Fund
  • Floating Point
  • Bertelsmann
  • Giant Ventures (existing investor)
  • Obvious Ventures (existing investor)

Startup Information

• Startup Name: Ataraxis AI
• Location: New York, USA
• Upcoming Product: First commercial test for breast cancer to be launched to U.S. oncologists in the coming months.

Additional Information

• Tech Validation: Ataraxis’s technology claims to be 30% more accurate than current standards for breast cancer detection.
• Long-Term Ambition: Aim to impact at least 50% of new cancer cases by 2030.

Feel free to ask if you need more details!

Source link

2025-03-05 18:54:39